A 5-year-old female presented to the ophthalmology clinic with one month of left upper eyelid ptosis and three months of intermittent wheezing and coughing. MRI of the brain and orbits revealed infiltrative enhancement involving both orbits, including the retro-maxillary space, maxillary sinus walls, greater wing of the sphenoid, and possibly the left cavernous sinus. She experienced acute respiratory decompensation in the setting of pansinusitis and tree-in-bud nodular pulmonary opacifications. Laboratory workup revealed anemia, thrombocytosis, and elevated inflammatory markers. An orbitotomy with biopsy demonstrated an eosinophil-rich granulomatous infiltrate, consistent with eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome. The patient was placed on high-dose steroids and mepolizumab. To our knowledge, this patient represents the youngest case of EGPA with orbital involvement. Further, this case illustrates the importance of prompt orbital biopsy to provide a timely, unified diagnosis, enabling specialists to initiate appropriate disease management to reduce morbidity and mortality.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/01676830.2024.2448813 | DOI Listing |
Rheumatology (Oxford)
March 2025
Nephrology and Dialysis Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
Hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA) both present with hypereosinophilia and organ damage induced by eosinophils. EGPA is also characterized by vasculitis and is associated with ANCA. Yet, discriminating HES from EGPA may be difficult in clinical practice as biomarkers to reliably differentiate between HES and EGPA are still lacking.
View Article and Find Full Text PDFRheumatology (Oxford)
March 2025
Vasculitis and Lupus Clinic, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
This session presented emerging realworld evidence on novel glucocorticoid (GC) sparing therapies for ANCA-associated vasculitis (AAV). It covered the first-in-class oral C5a receptor antagonist avacopan for severe granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), and antiinterleukin-5 therapies in the management of eosinophilic granulomatosis with polyangiitis (EGPA). Avacopan was approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of AAV in 2021, following the phase 3 ADVOCAT E trial comparing oral avacopan to an oral GC taper for GPA and MPA.
View Article and Find Full Text PDFMod Rheumatol
March 2025
Health Economics and Payer Evidence, AstraZeneca, Cambridge, UK.
Objective: To conduct a systematic literature review and meta-analysis for the incidence, prevalence and mortality of eosinophilic granulomatosis with polyangiitis (EGPA) and describe the clinical burden of EGPA.
Methods: Searches were conducted in Ovid MEDLINE and Ovid Embase from January 2019 to June 2023 to identify relevant studies. Data were extracted, and the quality was assessed.
BMJ Case Rep
March 2025
General Internal Medicine, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.
We describe the case of a 73-year-old man who had been followed up by our clinic for pulmonary hypertension and asthma. He was later hospitalized and found to have significant and persistent eosinophilia compatible with hypereosinophilic syndrome. Various other conditions such as drug reaction with eosinophilia and systemic symptoms (DRESS), malignancy, and eosinophilic granulomatosis with polyangiitis (EGPA) were considered but largely excluded after further investigation.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!